The possibility of psychiatric side effects may be to blame for the demise of two diet drugs. French drugmaker Sanofi-Aventis said it’s stopping all research on Accomplia – a diet drug sold in Europe. Just a few hours later, Pfizer Inc. announced it’s ending research on an experimental weight-loss drug in the same class.
Two weeks ago, Sanofi-Aventis temporarily stopped sales of Accomplia in Europe after reports that the drug’s risks – depression, anxiety and stress disorders – outweighed its benefits.
